HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.

Abstract
Somatostatin (SMS) scintigraphy is widely used for the detection and staging of neuroendocrine tumours. Because of its superior imaging properties, there is growing interest in the use of positron emission tomography (PET) technology for SMS scintigraphy. This study addressed the production of gallium-68 DOTATOC, its biokinetics and its clinical performance in detecting SMS-positive tumours and metastases. A preparation protocol was developed, yielding 40% overall incorporation of (68)Ga into the peptide (DOTATOC). After column filtration, the radiochemical purity exceeded 98%. Eight patients with histologically verified carcinoid tumours were injected with 80-250 MBq of this tracer. PET acquisition was initiated immediately after administration and carried out until 3 h post injection. Images were quantitated using standardised uptake values and target to non-target ratios. Prior to (68)Ga-DOTATOC PET, all patients underwent indium-111 octreotide planar and single-photon emission tomographic (SPET) imaging. Arterial activity elimination was bi-exponential, with half-lives of 2.0 (+/-0.3) min and 48 (+/-7) min. No radioactive metabolites were detected within 4 h in serum. Maximal tumour activity accumulation was reached 70+/-20 min post injection. Kidney uptake averaged <50% compared with spleen uptake. Of 40 lesions predefined by computed tomography and/or magnetic resonance imaging, (68)Ga-DOTATOC PET identified 100%, whereas (111)In-octreotide planar and SPET imaging identified only 85%. Tumour to non-tumour ratios ranged from >3:1 for liver ((111)In-octreotide: 1.5:1) to 100:1 for CNS ((111)In-octreotide: 10:1). With (68)Ga-DOTATOC >30% additional lesions were detected. It is concluded that PET using (68)Ga-DOTATOC results in high tumour to non-tumour contrast and low kidney accumulation and yields higher detection rates as compared with (111)In-octreotide scintigraphy.
AuthorsM Hofmann, H Maecke, R Börner, E Weckesser, P Schöffski, L Oei, J Schumacher, M Henze, A Heppeler, J Meyer, H Knapp
JournalEuropean journal of nuclear medicine (Eur J Nucl Med) Vol. 28 Issue 12 Pg. 1751-7 (Dec 2001) ISSN: 0340-6997 [Print] Germany
PMID11734911 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Gallium Radioisotopes
  • Indium Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Octreotide
  • Edotreotide
Topics
  • Aged
  • Carcinoid Tumor (pathology, radionuclide imaging)
  • Female
  • Gallium Radioisotopes
  • Humans
  • Indium Radioisotopes
  • Liver Neoplasms (radionuclide imaging, secondary)
  • Male
  • Middle Aged
  • Octreotide (analogs & derivatives, pharmacokinetics)
  • Radiopharmaceuticals
  • Receptors, Somatostatin (metabolism)
  • Tomography, Emission-Computed
  • Tomography, Emission-Computed, Single-Photon

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: